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Distinct Effects of Allelic NFIX Mutations
on Nonsense-Mediated mRNA Decay Engender
Either a Sotos-like or a Marshall-Smith Syndrome
Vale´rie Malan,1 Diana Rajan,2,11 Sophie Thomas,1,11 Adam C. Shaw,3 He´le`ne Louis dit Picard,1
Vale´rie Layet,4 Marianne Till,5 Arie van Haeringen,6 Geert Mortier,7 Sheela Nampoothiri,8
Silvija Puseljic,9 Laurence Legeai-Mallet,1 Nigel P. Carter,2 Michel Vekemans,1 Arnold Munnich,1
Raoul C. Hennekam,10 Laurence Colleaux,1,12,* and Vale´rie Cormier-Daire1,12,*
By using a combination of array comparative genomic hybridization and a candidate gene approach, we identified nuclear factor I/X
(NFIX) deletions or nonsense mutation in three sporadic cases of a Sotos-like overgrowth syndrome with advanced bone age, macroce-
phaly, developmental delay, scoliosis, and unusual facies. Unlike the aforementioned human syndrome, Nfix-deficient mice are unable
to gain weight and die in the first 3 postnatal weeks, while they also present with a spinal deformation and decreased bone mineraliza-
tion. These features prompted us to consider NFIX as a candidate gene for Marshall-Smith syndrome (MSS), a severe malformation
syndrome characterized by failure to thrive, respiratory insufficiency, accelerated osseous maturation, kyphoscoliosis, osteopenia, and
unusual facies. Distinct frameshift and splice NFIX mutations that escaped nonsense-mediated mRNA decay (NMD) were identified
in nine MSS subjects. NFIX belongs to the Nuclear factor one (NFI) family of transcription factors, but its specific function is presently
unknown.We demonstrate thatNFIX is normally expressed prenatally during human brain development and skeletogenesis. These find-
ings demonstrate that allelic NFIX mutations trigger distinct phenotypes, depending specifically on their impact on NMD.Introduction
Overgrowth syndromes are defined on a height more than
þ2 standard deviations (SD) often present at birth and
persistent in postnatal life. They tend to share several char-
acteristics including macrocephaly, mental retardation,
facial dysmorphic features, advanced bone age, hemihy-
perplasia, vascular malformations, and neoplasia but are
distinct by the specific combination of these features.
The molecular causes of several overgrowth conditions
such as Beckwith-Wiedemann syndrome (BWS [MIM
130650], Sotos syndrome (SS [MIM 117550]), Weaver
syndrome (WS [MIM 277590]), or Simpson-Golabi-Behmel
syndrome (SGBS [MIM 312870]) have been elucidated in
recent years. The etiology of BWS is complex, involving
a myriad of alterations to imprinted gene function in the
chromosome 11p15 region.1 SS and some WS cases are
caused by haploinsufficiency of the Nuclear receptor Set
Domain containing protein 1 gene (MIM 606681), NSD1,2
which encodes a developmental regulatory protein exert-
ing function(s) essential for early postimplantation devel-
opment. NSD1 SET domain possesses intrinsic histone
methyltransferase activity with specificity for Lys36 of1INSERM U781 and De´partement de Ge´ne´tique, Universite´ Paris Descartes, H
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Finally, SGBS3 is due to mutations in GPC3 (MIM 300037,
Glypican 3), which encodes an extracellular proteoglycan
interacting with the insulin-like growth factor IGF2 and
acting as a negative regulator of cell proliferation. Interest-
ingly, several chromosomal duplications and deletions
have been identified in patients with overgrowth, suggest-
ing that some still unclassified overgrowth syndromes
may be caused by subtle genomic imbalanced rearrange-
ments. Tall stature is observed in patients with dup(4)
(p16.3), probably due to dosage effect of the fibroblast
growth factor receptor gene 3 (FGFR3 [MIM 134934]).4
Trisomy of 15q26-qter is frequently associated with tall
stature and mental retardation caused by duplication of
the IGF1R gene (MIM 147370).5 Finally, del(22)(q13) has
also been associated with overgrowth and macrocephaly.6
Despite these recent advances, the disease-causing
mechanisms remain unknown in 20%–40% of overgrowth
cases. We recently reported a 1 Mb array-based compara-
tive genomic hybridization (array-CGH) analysis of 93
patients with syndromic overgrowth. Our results identified
nonrecurrent pathogenic chromosomal imbalances in 5%
of cases.7 However, a large majority of patients remainedoˆpital Necker-Enfants Malades, Paris 75015, France; 2The Wellcome Trust
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Figure 1. Genetic Analyses of Patients with Syndromic Overgrowth
(A) The figure shows the Ensembl display of the 19p13.2p13.3 region. Position of nonoverlapping NFIX deletions detected in patients
A and B are represented by squares. For patient A, we found the proximal and distal breakpoints at 12 898 751 and 13 006 539 bp, respec-
tively. For patient B, we found the proximal and distal breakpoints at 13 022 358 bp and 13 126 508 bp, respectively.
(B) The diagram shows the different mutations identified in NFIX genomic DNA. Open boxes represent untranslated regions and filled
boxes represent coding regions. Mutation in green corresponds to the Sotos-like case while those in red indicate mutations found inMSS
cases.
(C) Representative sequence traces of exon 3 in genomic DNA (top) or cDNA (bottom) of patient C (c.568C>T).
(D) Representative sequence traces of exon 8 sequences from genomic DNA (top) or cDNA (bottom) of patient F (c.1243 delG).without a known molecular etiology. We speculated that
we failed to detect small cryptic rearrangement with the
BAC-array used. This prompted us to evaluate unexplained
cases with overgrowth via a higher resolution (Agilent
244K oligonucleotide) array-CGH. We present here the
results of this analysis leading to the identification of
NFIX (MIM 164005) deletions and point mutations in
two distinct human disorders, a syndrome that shows190 The American Journal of Human Genetics 87, 189–198, August 1some resemblance to SS and Marshall-Smith syndrome
(MSS [MIM 602535]).
Subjects and Methods
Patients
For the 244K array-CGH, 18 patients and their parents were
selected. Inclusion criteria were (1) unrelated parents; (2)3, 2010
Figure 2. Front Views of the Three Overgrowth Syndrome
Patients
Note the high forehead, long narrow face (patients A and C), and
slender habitus.developmental delay; (3) height >95th percentile and/or occipito-
fronto circumference >95th percentile; and (4) at least two of
the following features: (i) advanced bone age, (ii) dysmorphic
craniofacial features, and (iii) congenital malformations.
For theNFIXmutations screening, 76 patients with unexplained
syndromic overgrowth were first screened. The second screen
tested 9 MSS patients fulfilling the diagnostic criteria for MS
syndrome.8
Array-CGH Analysis
Blood samples from patients and unaffected relatives were
obtained with the appropriate written informed consent, in accor-
dance with the French ethical standards regarding human
subjects, and genomic DNA was isolated from blood leucocytes
with the Nucleon kit (Amersham) according to the manufacturer’s
instructions. Sample labeling for array-CGH was performed as
described previously9 with 300 ng of input DNA. Array-CGH was
performed on Agilent 244K oligonucleotide arrays (Agilent, Santa
Clara, CA), according to the manufacturer’s protocols.
Mutation Screening of NFIX
Specific primers for PCR amplification of exons and splicing junc-
tions of NFIX were designed based on its sequence data from the
GenBank database (primer sequences are available in Table S1
available online). PCR products were purified with Exo-SAP (Amer-
sham) and directly sequenced on an automated sequencer (ABI
3130xl, Applied Biosystems) with the Dye Terminator method.
Expression Analyses of NFIX by RT-PCR
Selected RNAs from the Total Human RNA Master Panel II (Clon-
tech) were subjected to reverse transcription with the SuperScript
first-strand synthesis system (Invitrogen). Specific primers for PCR
amplification NFIX and Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) mRNA were designed based on their sequence
data from the GenBank database.
In Situ Hybridization
Normal human embryos and fetal tissues were obtained after
elective pregnancy termination in agreement with French legisla-
tion (law no. 2004-800), National Ethics Committee recommen-
dations (report no. 1 of May 22, 1984), and the Necker Hospital
ethics committee. Embryonic stages were established according
to Carnegie staging (CS) classification. Adjacent sections of
human embryos and fetuses were treated with antisense or
with control sense riboprobes. Riboprobe labeling, tissue fixation,
and hybridization were carried out according to standard
protocols.10Results
Array-CGH Analysis
Only de novo imbalances were further analyzed and the
Database of Genomic Variants was used to exclude CNVs
previously observed in control individuals. An abnormal
pattern in two patients (patients A and B) was suggestive
of a de novo 19p13.1monosomy (Figure 1A). FISH analyses
on metaphases and nuclei from blood lymphocytes via
fosmid clones G248P84002A10 and G248P87616F9 for
patient A and G248P87556E1 and G248P80518H5 forThe Americpatient B confirmed array-CGH findings. The deletions
involved a single common gene, nuclear factor I X-type,
NFIX, which was therefore regarded as a strong candidate
to cause the overgrowth in these patients (Figure 1A).Mutation Screening of NFIX
A total of 76 patients with unexplained syndromic over-
growth were screened for NFIX mutations. The NFIX tran-
scription unit encompasses 11 exons and encodes 6 iso-
forms that differ by alternative splicing of exon 7 and 9
and the use of alternative transcription initiation sites.
A heterozygote de novo c.568C>T transition within exon
3 predicting a p.190Q>X nonsense mutation and causing
premature translation termination codon (PTC) was iden-
tified in one patient (patient C diagnosed as ‘‘Sotos-like
syndrome’’ based on slightly different facial features,
Figures 1B and 2). This variant was not observed in 300
control chromosomes. Patients A–C presented a very
similar phenotype consisting of postnatal overgrowth,
macrocephaly, advanced bone age, long narrow face,
high forehead, slender habitus, scoliosis, unusual behavior
characterized especially by anxiety, andmental retardation
(Figure 2, Table 1).
Two Nfix-deficient mice with marked differences in
phenotypes have been described.11,12 They have distinct
phenotypes but in one model, Nfix/ newborn mice
fail to thrive by P5, have a progressive kyphosis, delayed
endochondral ossification, and reduction of trabecular
bone formation, and usually die between days P21 andan Journal of Human Genetics 87, 189–198, August 13, 2010 191
Table 1. Clinical Details of Patients with 19p13.1 Monosomy and
c.568C>T NFI-X Mutation
Patient A Patient B Patient C
NFIX deletion/mutation del 19p13.3 del 19p13.3 c.568C>T
Age at the last
examination (yr)
14 10 27
Sex M M F
Age mother/father (yr) 31/33 25/30 31/31
Ethnic origin French French French
Prenatal growth
Birth weight (g) (centile) 4500 (>95) 3110 (10–50) 3600 (50–90)
Birth height (cm) (centile) 53 (95) 49 (50) 52 (95)
OFC (cm) (centile) 38 (>95) 33.5 (10) 37.5 (>95)
Feeding problems in
neonatal period
þ þ
Postnatal growth
Height > P98 þ þ þ
OFC > P98 þ þ þ
Height-weight ratio < P25 þ þ
Developmental characteristics
Mental retardation þ þ þ
Speech delay þ þ þ
Autistic traits þ þ þ
Behavioral anomalies þ þ þ
Motor retardation þ
Hypotonia þ þ
Brain MRI
Ventricular dilatation/
hypoplasia corpus
callosum
þ
Ventricular dilatation þ
Craniofacial features
Long/narrow face þ þ þ
High forehead þ þ þ
Down-slanting palpebral
fissures
þ þ
Small mouth þ þ
Everted lower lip þ þ
Prognathia þ
Eyes
Hypermotropia þ þ
Strabismus þ þ
Nystagmus þ
Astigmatism þ
Musculo-skeletal abnormalities
Pectus excavatum þ þ
Table 1. Continued
Patient A Patient B Patient C
Scoliosis þ þ
Advanced bone age þ þ þ
Abdominal wall
hypotonia
þ þ
Coxa valga þ þ
Hand/foot abnormalities
Long fingers þ þ
Other abnormalities
Malformed nails þ
Premature eruption of
teeth
þ
Generalized livedo þ
192 The American Journal of Human Genetics 87, 189–198, August 1P28.11 These features were reminiscent of Marshall-Smith
syndrome,8 which prompted us to consider NFIX as
a candidate gene for MSS. Therefore, we screened nine
MSS patients (Figure 3 and Table 2) forNFIXmutations and
found seven independent heterozygous frameshift muta-
tions (c.1011_1012 delTCfsX84, c.1037_1038insTfsX76,
c.1008_1012 delCTCTCfsX83, c.1048_1049insCfsX70,
c.1243 delGfsX48, c.994_995insTfsX88, c.959_
960insCfsX10). In addition, two mutations were identified
within the donor-splice site of exon 6 (c.955þ1G>A,
c.955þ1G>T) (Figure 1B). All mutations occurred de
novo and were not found in a panel of 300 control
chromosomes.
RT-PCR Analyses of NFIX
To study the consequences of mutations causing either
overgrowth or MSS on RNA level, we extracted, reverse
transcribed, and sequenced RNA from skin fibroblasts of
the overgrowth patient (patient C) and two MSS patients
with a NFIX mutation. In the overgrowth patient, a single
wild-type allele was observed (Figure 1C). In contrast, the
MSS patients showed expression of both normal and
mutated alleles (Figure 1D; Figures S1A and S1B). Similarly,
RT-PCR analysis of RNA extracted of skin fibroblasts
from the MSS patient carrying the c.955þ1G>A mutation
(disrupting proper mRNA splicing and causing partial
inclusion of intron 6) detected both wild-type andmutated
alleles (Figure S1C).
In Situ Hybridization
To gain insight into the function of NFIX gene product and
establish correlationswith the clinicalmanifestations of the
patients, we studied the expression of NFIX in various
humanembryos and fetal andadult tissues. RT-PCRanalysis
demonstrated an ubiquitous expression of NFIX in the
humancell types and tissues tested, including chondrocytes
and osteoblasts (Figure S2). In situ hybridization in normal
human embryos at CS17 (gestational day 42 [d42]) showed3, 2010
Figure 3. Pictures and Hand and Foot X-Rays of
Patients with Marshall-Smith Syndrome
Facial features of the nine patients with Marshall-Smith
syndrome (A–I) and hand X-rays at 1 year (J) and 4 years
(K) of age and foot X-rays at 1 year of age (L). Note
the high forehead, proptosis, underdeveloped midface,
the advanced carpal and tarsal ossification, and the
abnormal wide, bullet-shaped phalanges.a nearly ubiquitous expression of NFIX, with prominent
expression in the central nervous systemand the peripheral
nervous system (Figures 4A–4E). In fetal brain (22 WG),
NFIX was expressed in the cerebral cortex, in the hippo-
campus, and faintly in the thalamus. Finally, in the
skeleton, NFIX expression was first noticed at CS17 in the
mandibular arch, the cartilage primordiumof the humerus,
the scapula, and the vertebrae. In the limb,NFIX expression
was first observed at CS17 in the perichondrium. At 14
weeks of gestation (WG), NFIX was highly expressed in
the proliferating zone of the digit (Figures 4F and 4G).
The study of distal femoral growth plates of 1- to 5-week-
old mice and human fetus revealed strong NFIX expres-
sion in bone and in prehypertrophic chondrocytes (Figures
4H–4M).Discussion
We report here NFIX deletions and nonsense mutation in
three patients with an overgrowth syndrome that shows
some resemblance to Sotos syndrome and which is charac-
terized by postnatal overgrowth, macrocephaly, advanced
bone age, long narrow face, high forehead, slender habitus,
scoliosis, anxiety, and mental retardation.
NFIX belongs to the Nuclear factor one (NFI) family of
transcription factors. Members of this family act as homo-
and heterodimers and bind with high affinity to the
palindromic consensus sequence TTGGC(N5)GCCAA.13
In vertebrates, the Nfi gene family consists of four closely
related genes (Nfia-c and Nfix).14,15 They encode proteins
with a conserved N-terminal DNA-binding and dimeriza-
tion domain16 and a C-terminal transactivation/repression
domain. Two Nfix-deficient mice with marked differencesThe American Journalin phenotypes have been described.11,12 They
have in common brain anomalies (enlarged
ventricles, corpus callosum agenesis, or expanded
cortex or distortion of the hippocampus) but
have distinct phenotypes from those observed
in overgrowth patients. In one model, Nfix/
newborn mice are indistinguishable from wild-
type and heterozygous littermates, but fail to
thrive by P5 and usually die between days P21
and P28.11 They also present with progressive
kyphosis, delayed endochondral ossification, and
reduction of trabecular bone formation. These
features resemble Marshall-Smith syndrome.8
MSS was first described in 1971 and was originallyconsidered an overgrowth condition based on the acceler-
ated skeletal maturation. Main features include high fore-
head, proptosis, blue sclerae, underdeveloped midface,
short nose, and retrognathia. The outcome is characterized
by mental retardation, failure to thrive, life-threatening
respiratory difficulties, and skeletal anomalies including
osteopenia, kyphoscoliosis, fractures, and hyperextensibil-
ity.8 The identification of NFIXmutations in the nine MSS
patients further demonstrates the usefulness of mouse
model in selecting candidate genes for human disorders.
The present results address the question of how allelic
NFIX mutations can cause two different phenotypes.
Either triggering or escaping NMD may explain this obser-
vation. Indeed, although nonsense and frameshift muta-
tions resulting in PTC are expected to be natural targets
of the NMD RNA surveillance system, several studies
have shown that escaping NMD may lead the translated
protein to convey potent dominant-negative or gain-of-
function effects.17–20 Whereas the overgrowth phenotype
is due to NFIX haploinsufficiency, the presence of both
normal and mutated alleles in MSS supports that mutated
RNAs escape NMD surveillance. We therefore suggest that
NFIX mutations causing MSS generate mutant proteins
able to exert a dominant-negative effect over the wild-
type allele and result in a more severe phenotype closely
resembling the Nfix/ mouse phenotype.
Previous reports have demonstrated that NMD can
modify phenotypes conveyed by allelic truncating muta-
tions. SOX10 (MIM602229) dominant-negativemutations
are responsible for a severe phenotype of peripheral demy-
elinating neuropathy, central dysmyelinating leukodys-
trophy, Waardenburg syndrome, and Hirschsprung disease
(PCWH syndrome [MIM609136]) whereas nonsensemuta-
tions activating NMD are responsible for the less severeof Human Genetics 87, 189–198, August 13, 2010 193
Table 2. Clinical Details of the Nine Patients with Marshall-Smith Syndrome
Patient 1 2 3 4 5 6 7 8 9
NFIX mutation c.955þ1G>A c.955þ1G>T
c.1011_1012
delTC
c.1037_
1038 insT
c.1008_1012
delCTCTC
c.1048_
1049 insC
c.1243
delG
c.994_
995 insT
c.959_
960 insC
Epidemiology
Gender M F M M F F M F M
Age at last examination 3 weeksa 6 months 26 months 3 years 6 years 7 years 7 years 16 years 21 years
Ethnic origin Belgium Croatia India Netherlands Brazil Portugal France UK UK
Growth
Birth weight (g) 2600 3400 2950 2975 1590 3230 2800 3860
Present weight (kg) 2965 5 9.1 15 21 35 41
Present height (cm) 55 68 82 100 103 120 131
Development
Degree of delay n.a. Sev Sev Mod Mod-Sev Mod Mod Sev Sev
First words (mths) n.a. n.a. - - 60 36 None None
Neurology
High tone - - - - - - N/A N/A
Brain MRI dilated
ventricles
pachygyria,
hypoplasia
callosal body
CTscan: N hypoplasia
callosal body
N/A N/A N/A N/A
Craniofacial features
High forehead þ þ þ þ þ þ þ þ þ
Proptosis þ þ þ þ þ þ þ þ þ
Underdeveloped midface þ þ þ þ þ - þ þ þ
Short nose þ þ þ þ - - þ þ þ
Prominent premaxilla þ þ þ þ þ þ þ þ þ
Everted lips - - - þ þ - þ þ þ
Gum hypertrophy - þ þ þ - þ - -
Retrognathia þ þ þ þ þ þ þ þ -
Eyes
Myopia - - - 14 5/-8 12/-9 - - -
Blue sclerae þ þ þ þ þ - þ þ þ
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Table 2. Continued
Patient 1 2 3 4 5 6 7 8 9
NFIX mutation c.955þ1G>A c.955þ1G>T
c.1011_1012
delTC
c.1037_
1038 insT
c.1008_1012
delCTCTC
c.1048_
1049 insC
c.1243
delG
c.994_
995 insT
c.959_
960 insC
Respiratory
Choanal stenosis - þ - - - þ - -
Respiratory problems þ þ - þ þ - þ - þ
Musculo-Skeletal
Abnormal bone maturation þ þ þ þ þ þ þ þ þ
Bone fractures - - - 1 - - 4 - -
Scoliosis - - - - þ - þ þ þ
Kyphosis - - - - þ þ þ þ þ
Umbilical hernia - þ - - - þ - -
Other
Cardiac defect - - - - VSD - VSD -
Hearing loss þ þ - þ - þ N/A N/A
Hypertrichosis - þ þ þ þ þ þ þ
Miscellaneous IgA deficiency;
vesico-ureteral
reflux; long
fingers
abnormal
pinnae
hypospadias;
glaucoma
long
fingers
pyloric
stenosis
Wilms
tumor
aged 4
Abbreviations: M, male; F, female; n.a., not applicable; N/A, not available; sev, severe; mod, moderate; VSD, ventricular septal defect.
a Deceased.
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Figure 4. Pattern of NFIX Expression in Early Human
Development and Fetal Epiphyseal Growth Plate
(A–G) Adjacent sections of human embryos and fetuses
treated with antisense (A–C, E–G) or with control sense
(D) riboprobes.
(A) Carnegie stage 17 (CS17) human embryo section.
(B–D) CS19 human embryo sections.
(E) Frontal section of a fetal (22WG) brain.
(F and G) Sagittal section of a fetal (14WG) hand.
The hybridization with control sense probe does not
give any signal (D).
Note the expression in the neuroepithelium of the pros-
encephalon, the mesencephalon, the rhombenceph-
alon, and the spinal cord as well as in the cranial and
dorsal root ganglia.
Abbreviations: Ah, Ammon’s horn; c, cerebral cortex;
co, cochlea; dg, dentate gyrus; di, diencephalon; drg,
dorsal root ganglia; fv, fourth ventricule; h, heart; hu,
humerus; ie, inner ear; la, lateral ventricule; li, liver;
lu, lung; M, mesencephalon; me, mesonephros; nt, neu-
roepithelium of the neural tube; oe, olfactory epithe-
lium; op, optic stalk; ot, otic vesicle; p, pons; pa, pharin-
gial arch; sca, scapula; st, stomach; T, Telencephalon; th,
thalamus; V, trigeminal ganglia; ve, cartilage primordia
of vertebrae.
(H–M) NFIX immunohistochemostry performed in
1-week-old mice (H), 2-week-old mice (I), 3-week-old
mice (J), 4-week-old mice (K), 5-week-old mice (L), and
20 weeks of gestation human fetus (M). Note the
restricted expression in the prehypertrophic chondro-
cytes and the expression in bone.
Abbreviations: of, ossification front, hy, hypertrophic
zone; PHy, prehypertrophic zone; Pro, proliferative
zone.phenotype combining Waardenburg and Hirschsprung
only.21 Similarly, either triggering or escaping NMD is
responsible for the various phenotypes caused by muta-
tions within the myelin protein zero (MIM 159440) or
elastin genes (MIM 130160).22–25 In mammalian cells, an
exon-exon junction complex of proteins deposited 20–24
nucleotides upstream of exon-exon junctions during pre-
mRNA splicing is considered to be a primary determinant
of NMD.26,27 Consequently, translation termination at a
nonsense codon located more than 50–55 nucleotides
upstream of an exon-exon junction generally triggers
NMD.Most of theNFIXmutations causingMSS that caused
PTCwere locatedmore than 50–55 nucleotides upstreamof
an exon-exon junction. Why these mutations escaped
NMD remains hitherto unexplained. Finally, one cannot
exclude variable consequences of the mutations on the six
different isoforms encoded by NFIX.
The NFI proteins have been shown to be involved in
replication, signal transduction, and transcription.28 The196 The American Journal of Human Genetics 87, 189–198, August 13, 2010NFI family has also been largely studied in respect
to brain development and loss of function of NFI
members in mice is associated with corpus cal-
losum agenesis, a feature observed in overgrowth
patients from this study. Our observation of
a prominent expression in the nervous system
in human embryo and of a specific expressionin fetal brain is also in agreement with the findings of
mental retardation in overgrowth and MSS patients.
Finally, the presence of a specific expression in prehyper-
trophic chondrocytes and bone is also in correlation with
the clinical manifestations observed in the two human
phenotypes, including advanced bone age in overgrowth
patients and advanced carpal ossification, kyphosis, and
osteopenia in MSS. Interestingly, the restricted expression
to the prehypertrophic chondrocytes is quite similar to
the parathyroid-related peptide receptor (PTHR1 [MIM
168468]) pattern of expression.29 These findings suggest
a key role of NFIX in chondrocyte differentiation and
bone formation and its specific involvement in the endo-
chondral ossification process. The overgrowth in patients
with dominant NFIX mutations supports a dysregulation
of the switch between proliferation and differentiation
stages and also suggests that NFIX could act as a negative
regulator of the endochondral ossification process. The
decreased bone density and spontaneous fractures in MSS
patients could be directly linked to the role of NFIX in bone
formation.
In conclusion, the present study demonstrates that NFIX
haploinsufficiency is responsible for anovel clinically recog-
nizable overgrowth syndrome condition and shows that
NFIX is a disease-causing gene ofMarshall-Smith syndrome.
We provide further evidence that nonsense-mediated
mRNA decay modulates the clinical consequences of the
mutations. Finally, our findings support a key role of NFIX
in human brain development and skeletogenesis.Supplemental Data
Supplemental Data include two figures and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
We are grateful to the patients and their family and to the French
association ‘‘L’e´veil’’ for their participation in the study. This study
was supported by the Centre National de la Recherche Scientifi-
que, the GIS-Maladies Rares, the Agence de BioMe´decine, and
the international Marshall-Smith Support group. The authors
declare no competing financial interests.
Received: June 18, 2010
Revised: July 6, 2010
Accepted: July 7, 2010
Published online: July 29, 2010Web Resources
The URLs for data presented herein are as follows:
Ensembl Genome Browser, http://www.ensembl.org/
National Center for Biotechnology Information, http://www.ncbi.
nlm.nih.gov/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/References
1. Weksberg, R., Smith, A.C., Squire, J., and Sadowski, P. (2003).
Beckwith-Wiedemann syndrome demonstrates a role for
epigenetic control of normal development. Hum. Mol. Genet.
12(Spec No 1), R61–R68.
2. Visser, R., and Matsumoto, N. (2003). Genetics of Sotos
syndrome. Curr. Opin. Pediatr. 15, 598–606.
3. Neri, G., Gurrieri, F., Zanni, G., and Lin, A. (1998). Clinical and
molecular aspects of the Simpson-Golabi-Behmel syndrome.
Am. J. Med. Genet. 79, 279–283.
4. Partington, M.W., Fagan, K., Soubjaki, V., and Turner, G.
(1997). Translocations involving 4p16.3 in three families:
Deletion causing the Pitt-Rogers-Danks syndrome and dupli-
cation resulting in a new overgrowth syndrome. J. Med.
Genet. 34, 719–728.
5. Faivre, L., Gosset, P., Cormier-Daire, V., Odent, S., Amiel, J.,
Giurgea, I., Nassogne, M.C., Pasquier, L., Munnich, A.,
Romana, S., et al. (2002). Overgrowth and trisomy 15q26.1-The Americqter including the IGF1 receptor gene: report of two families
and review of the literature. Eur. J. Hum. Genet. 10, 699–706.
6. Phelan, M.C., Rogers, R.C., Saul, R.A., Stapleton, G.A., Sweet,
K., McDermid, H., Shaw, S.R., Claytor, J., Willis, J., and Kelly,
D.P. (2001). 22q13 deletion syndrome. Am. J. Med. Genet.
101, 91–99.
7. Malan, V., Chevallier, S., Soler, G., Coubes, C., Lacombe, D.,
Pasquier, L., Soulier, J., Morichon-Delvallez, N., Turleau, C.,
Munnich, A., et al. (2010). Array-based comparative genomic
hybridization identifies a high frequency of copy number vari-
ations in patients with syndromic overgrowth. Eur. J. Hum.
Genet. 18, 227–232.
8. Adam, M.P., Hennekam, R.C., Keppen, L.D., Bull, M.J., Cleri-
cuzio, C.L., Burke, L.W., Ormond, K.E., and Hoyme, E.H.
(2005). Marshall-Smith syndrome: Natural history and
evidence of an osteochondrodysplasia with connective tissue
abnormalities. Am. J. Med. Genet. A. 137, 117–124.
9. Fiegler, H., Geigl, J.B., Langer, S., Rigler, D., Porter, K., Unger,
K., Carter, N.P., and Speicher, M.R. (2007). High resolution
array-CGH analysis of single cells. Nucleic Acids Res. 35, e15.
10. Delous, M., Baala, L., Salomon, R., Laclef, C., Vierkotten, J.,
Tory, K., Golzio, C., Lacoste, T., Besse, L., Ozilou, C., et al.
(2007). The ciliary gene RPGRIP1L is mutated in cerebello-
oculo-renal syndrome (Joubert syndrome type B) and Meckel
syndrome. Nat. Genet. 39, 875–881.
11. Driller, K., Pagenstecher, A., Uhl, M., Omran, H., Berlis, A.,
Grunder, A., and Sippel, A.E. (2007). Nuclear factor I X defi-
ciency causes brain malformation and severe skeletal defects.
Mol. Cell. Biol. 27, 3855–3867.
12. Campbell, C.E., Piper, M., Plachez, C., Yeh, Y.T., Baizer, J.S.,
Osinski, J.M., Litwack, E.D., Richards, L.J., and Gronostajski,
R.M. (2008). The transcription factor Nfix is essential for
normal brain development. BMC Dev. Biol. 8, 52.
13. Roulet, E., Bucher, P., Schneider, R., Wingender, E., Dusserre,
Y., Werner, T., and Mermod, N. (2000). Experimental analysis
and computer prediction of CTF/NFI transcription factor DNA
binding sites. J. Mol. Biol. 297, 833–848.
14. Rupp, R.A., Kruse, U., Multhaup, G., Gobel, U., Beyreuther, K.,
and Sippel, A.E. (1990). Chicken NFI/TGGCA proteins are
encoded by at least three independent genes: NFI-A, NFI-B
and NFI-C with homologues in mammalian genomes. Nucleic
Acids Res 18, 2607–2616.
15. Kruse, U., Qian, F., and Sippel, A.E. (1991). Identification of
a fourth nuclear factor I gene in chicken by cDNA cloning:
NFI-X. Nucleic Acids Res. 19, 6641.
16. Gounari, F., De Francesco, R., Schmitt, J., van der Vliet, P.,
Cortese, R., and Stunnenberg, H. (1990). Amino-terminal
domain of NF1 binds to DNA as a dimer and activates adeno-
virus DNA replication. EMBO J. 9, 559–566.
17. Mendell, J.T., and Dietz, H.C. (2001). When the message goes
awry: Disease-producing mutations that influence mRNA
content and performance. Cell 107, 411–414.
18. Holbrook, J.A., Neu-Yilik, G., Hentze, M.W., and Kulozik, A.E.
(2004). Nonsense-mediated decay approaches the clinic.
Nat. Genet. 36, 801–808.
19. Kuzmiak, H.A., and Maquat, L.E. (2006). Applying nonsense-
mediated mRNA decay research to the clinic: Progress and
challenges. Trends Mol. Med. 12, 306–316.
20. Chang, Y.F., Imam, J.S., and Wilkinson, M.F. (2007). The
nonsense-mediated decay RNA surveillance pathway. Annu.
Rev. Biochem. 76, 51–74.an Journal of Human Genetics 87, 189–198, August 13, 2010 197
21. Cossais, F., Wahlbuhl, M., Kriesch, J., and Wegner, M. (2010).
SOX10 structure-function analysis in the chicken neural tube
reveals important insights into its role in human neurocristo-
pathies. Hum. Mol. Genet. 19, 2409–2420.
22. Warner, L.E., Hilz, M.J., Appel, S.H., Killian, J.M., Kolodry,
E.H., Karpati, G., Carpenter, S., Watters, G.V., Wheeler, C.,
Witt, D., et al. (1996). Clinical phenotypes of different MPZ
(P0) mutations may include Charcot-Marie-Tooth type 1B,
Dejerine-Sottas, and congenital hypomyelination. Neuron
17, 451–460.
23. Inoue, K., Khajavi, M., Ohyama, T., Hirabayashi, S., Wilson, J.,
Reggin, J.D., Mancias, P., Butler, I.J., Wilkinson, M.F., Wegner,
M., et al. (2004). Molecular mechanism for distinct neurolog-
ical phenotypes conveyed by allelic truncating mutations.
Nat. Genet. 36, 361–369.
24. Metcalfe, K., Rucka, A.K., Smoot, L., Hofstadler, G., Tuzler, G.,
McKeown, P., Siu, V., Rauch, A., Dean, J., Dennis, N., et al.
(2000). Elastin: Mutational spectrum in supravalvular aortic
stenosis. Eur. J. Hum. Genet. 8, 955–963.198 The American Journal of Human Genetics 87, 189–198, August 125. Micale, L., Turturo, M.G., Fusco, C., Augello, B., Jurado, L.A.,
Izzi, C., Digilio, M.C., Milani, D., Lapi, E., Zelante, L., et al.
(2010). Identification and characterization of seven novel
mutations of elastin gene in a cohort of patients affected by
supravalvular aortic stenosis. Eur. J. Hum. Genet. 18, 317–323.
26. Le Hir, H., Izaurralde, E., Maquat, L.E., andMoore, M.J. (2000).
The spliceosome deposits multiple proteins 20-24 nucleotides
upstream of mRNA exon-exon junctions. EMBO J. 19,
6860–6869.
27. Le Hir, H., Gatfield, D., Izaurralde, E., and Moore, M.J. (2001).
The exon-exon junction complex provides a binding platform
for factors involved in mRNA export and nonsense-mediated
mRNA decay. EMBO J. 20, 4987–4997.
28. Gronostajski, R.M. (2000). Roles of the NFI/CTF gene family in
transcription and development. Gene 249, 31–45.
29. Hopyan, S., Gokgoz, N., Poon, R., Gensure, R.C., Yu, C., Cole,
W.G., Bell, R.S., Juppner, H., Andrulis, I.L., Wunder, J.S., et al.
(2002). Amutant PTH/PTHrP type I receptor in enchondroma-
tosis. Nat. Genet. 30, 306–310.3, 2010
